P
Peter Martin
Researcher at NewYork–Presbyterian Hospital
Publications - 216
Citations - 8480
Peter Martin is an academic researcher from NewYork–Presbyterian Hospital. The author has contributed to research in topics: Mantle cell lymphoma & Follicular lymphoma. The author has an hindex of 38, co-authored 179 publications receiving 6862 citations. Previous affiliations of Peter Martin include Cornell University & BC Cancer Agency.
Papers
More filters
Journal ArticleDOI
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang,Simon Rule,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Lei Li,Liang Zhang,Kate J. Newberry,Zhishuo Ou,Nancy Cheng,Bingliang Fang,Jesse McGreivy,Fong Clow,Joseph J. Buggy,Betty Y. Chang,Darrin M. Beaupre,Lori Kunkel,Kristie A. Blum +31 more
TL;DR: Ibrutinib shows durable single-agent efficacy in relapsed or refractory mantle-cell lymphoma and is enrolled into two groups: patients who had previously received at least 2 cycles of bortezomib therapy and those who had received less than 2 complete cycles.
Journal ArticleDOI
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
Ajay K. Gopal,Ajay K. Gopal,Brad S. Kahl,Sven de Vos,Nina D. Wagner-Johnston,Stephen J. Schuster,Wojciech Jurczak,Ian W. Flinn,Christopher R. Flowers,Peter Martin,Andreas Viardot,Kristie A. Blum,Andre Goy,Andrew Davies,Pier Luigi Zinzani,Martin Dreyling,Dave Johnson,Langdon L. Miller,Leanne Holes,Daniel Li,Roger Dansey,Wayne R. Godfrey,Gilles Salles +22 more
TL;DR: In this single-group, open-label, phase 2 study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment.
Journal ArticleDOI
Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
Michael L. Wang,Kristie A. Blum,Peter Martin,Andre Goy,Rebecca Auer,Brad S. Kahl,Wojciech Jurczak,Ranjana H. Advani,Jorge E. Romaguera,Michael E. Williams,Jacqueline C. Barrientos,Ewa Chmielowska,John Radford,Stephan Stilgenbauer,Martin Dreyling,Wiesław Wiktor Jędrzejczak,Peter Johnson,Stephen E. Spurgeon,Liang Zhang,Linda Baher,Mei Cheng,Dana Lee,Darrin M. Beaupre,Simon Rule +23 more
TL;DR: With longer follow-up, ibrutinib continues to demonstrate durable responses and favorable safety in relapsed/refractory MCL and is approved for patients with mantle cell lymphoma who have received one prior therapy.
Journal ArticleDOI
Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma
Peter Martin,Amy Chadburn,Paul J. Christos,Karen Weil,Richard R. Furman,Jia Ruan,Rebecca Elstrom,Ruben Niesvizky,Scott Ely,Maurizio DiLiberto,Ari Melnick,Daniel M. Knowles,Selina Chen-Kiang,Morton Coleman,John P. Leonard +14 more
TL;DR: In selected asymptomatic patients with MCL, deferred initial treatment ("watch and wait") is an acceptable management approach and time to treatment did not predict overall survival in a multivariate analysis.
Journal ArticleDOI
Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma
Jia Ruan,Peter Martin,Richard R. Furman,Shing M. Lee,Ken Cheung,Julie M. Vose,Ann S. LaCasce,Julia Morrison,Rebecca Elstrom,Scott Ely,Amy Chadburn,Ethel Cesarman,Morton Coleman,John P. Leonard +13 more
TL;DR: Bortezomib with R-CHOP-21 can be safely administered and may enhance outcomes, particularly in non-GCB DLBCL, justifying randomized studies and IPI and MIPI correlated with survival inDLBCL and MCL.